Introduction
============

In traditional medicine, it is believed that the kidney is the congenital foundation of the human body, and it produces and stores an "essence." The kidney was believed to play an important role in governing water, the vascular system, the heart, growth and the brain in ancient China, as shown in Figure [1](#F1){ref-type="fig"}. This means the kidney modulates the brain through the "essence" it produces. The "energy" in the brain would be insufficient if the "essence" in the kidney were lacking, resulting in cognitive function decline ([@B42]). Images of the brain taken by MRI of patients with kidney essence deficiency syndrome have similar imaging patterns to the brains of AD patients ([@B26]).

![The function of kidney in Traditional Chinese Medicine. The kidney store essence, and it governs brain through the essence. Besides, the kidney governs the water, vascular, heart, and growth in ancient China.](fncel-12-00384-g001){#F1}

In 2012, a systematic meta-analysis of 54779 patients showed that the risk of cognitive impairment is significantly higher in patients with CKD than in patients without CKD (*p* \< 0.001) ([@B22]). CKD is characterized by a glomerular filtration rate (GFR) of less than 60 mL/min per 1⋅73 m^2^ or renal damage (structural or functional) for at least 3 months ([@B26]). Patients with CKD are prone to cognitive impairment at each phase ([@B13]). The lower the renal function in CKD patients is, the greater is the risk of cognitive impairment ([@B19]). Moreover, it has been found that a successful renal transplantation can significantly improve or even reverse cognitive impairment in patients with renal failure and the memory disorders that appeared during dialysis ([@B55]; [@B27]). Furthermore, the improvement in cognitive function is closely related to renal function after transplantation and the stage of the patient's CKD ([@B30]).

The kidney is the organ with the highest blood flow in the human body, as calculated by the blood flow per gram of organ. The high blood flow rate of the kidney far exceeds the needs of its own metabolism. In a sense, we understand that the kidney is an organ composed of large numbers of blood vessels that help maintain the stability of its internal environment. The blood flow through the kidneys is very fast, approximately 1200 mL per minute in a resting, healthy, normal adult, which is approximately 20--25% of the total cardiac output; moreover, the blood running through the kidneys is filtered and reabsorbed to excrete metabolic waste from the body and maintain the stability of the internal environment (the internal environment is the environment where the cells live directly in the body) ([@B61]).

The oxygen consumption of the human brain is approximately 1/5 that of the whole body, and the amount of blood reaching the human brain is approximately 15% of the total cardiac output. The cerebral cortex is very sensitive to ischemia and hypoxia of the cerebral blood circulation ([@B6]; [@B17]). Normal blood pressure levels allow the brain to obtain a sufficient cerebral blood supply. The balance of blood pressure relies on the complex regulatory mechanisms of neurohumoral systems, which involve all organs of the body, and the kidney is the hub of the blood pressure regulation system ([@B4]).

In the clinic, CKD is divided into 5 stages. Patients with CKD~1~ or CKD~2~ have mild renal injury, patients with CKD~3~ or CKD~4~ have moderate to severe renal injury, and stage CKD~5~ is end-stage renal disease (ESRD) or renal failure, requiring dialysis. CKD promotes the progression of AD ([@B22]), which may be an opportunity but also a challenge for early AD diagnosis and treatment; additionally, the number of CKD patients is growing fast. For example, in 2012, the first multicenter study on CKD in China showed that the prevalence of AD was 10.8% in 50550 patients, and this rate exhibited an upward trend year by year ([@B74]). In 2008, there were 65074 ESRD patients undergoing hemodialysis or peritoneal dialysis in China, the main factors threatening hemodialysis patients were cardiovascular and cerebrovascular diseases (i.e., stroke) ([@B76]), and the raw annual mortality of patients undergoing maintenance hemodialysis in Beijing is gradually increasing ([@B14]).

Alzheimer's disease is a chronic progressive neurodegenerative disorder causing a significant cognitive deficit, and it is one of the most common types of dementia. A substantial amount of money and human resources is devoted to treating AD every year. The expenses associated with AD greatly increase the social, economic and medical burden of the disease. In 2016, there were 5.4 million AD patients who spent approximately \$236 billion in the United States ([@B3]). However, the pathogenesis of AD is still not clear, and there is no effective treatment for AD at present. However, the fact that CKD promotes the development of cognitive decline and AD results in a new field for exploring the pathogenesis of AD and sheds light on possibilities for the prevention and treatment of AD.

Mechanisms of Cognitive Decline and AD Related to CKD
=====================================================

Vascular Injury
---------------

Vascular stiffness is defined as diminished vascular elasticity, and the duration of blood vessel expansion is extended. Vascular calcification is usually characterized by the formation of vascular stiffness, manifested as the excessive deposition of calcium on the vascular walls. Vascular stiffness and calcification are common types of vascular injuries. Vascular stiffness is observed in the progression of CKD ([@B50]), and vascular stiffness is significantly associated with cognitive impairment ([@B54]). Interestingly, proteinuria and vascular stiffness are significantly correlated in AD patients, suggesting that vascular injury is involved in some pathological processes of AD in CKD patients ([@B52]).

As mentioned above, vascular disease is significantly more common in patients with CKD, and it is mainly caused by accumulated uremic toxin due to renal dysfunction. The European Uremic Toxin Work Group has listed more than 90 kinds of uremic toxins, such as phosphorus, aluminum, and ADMA (asymmetric dimethylarginine) ([@B73]). The accumulation of phosphorus promotes vascular calcification ([@B60]). In addition, an increase in ADMA in serum is related to vascular stiffness and cerebral blood flow in healthy people; this phenomenon is generally considered a potential early biomarker and can also be explained by impairment of the endothelium dependent on vasodilatation caused by ADMA ([@B2]). Moreover, it is also important in the regulation of cerebral blood vessels ([@B5]).

The elevation of plasma Hcy (serum homocysteine) is a strong risk factor of AD and vascular disease ([@B43]; [@B62]). There is a mass accumulation of Hcy in patients with CKD, probably because the Hcy clearance ability is damaged in patients with renal dysfunction ([@B35]; [@B53]). We know that vascular injury can be caused by elevated Hcy through endothelial dysfunction in patients with CKD ([@B40]), suggesting that cognitive decline and/or AD is caused by Hcy through vascular endothelial dysfunction in CKD patients.

Direct Neurotoxicity of Uremic Toxins
-------------------------------------

The massive accumulation of urinary toxins can directly act on multiple organs in the body through blood flow. For example, there is a large accumulation of parathyroid hormone (PTH) in the blood when patients have renal dysfunction. PTH can pass through the blood-brain barrier, and one study found that the PTH2 receptor was widely distributed in the central nervous system ([@B20]). It has also been shown that PTH is closely related to cognitive function ([@B45]) and that cognitive function can be improved after parathyroidectomy in patients with secondary hyperparathyroidism, suggesting that renal dysfunction-induced accumulation of PTH affects cognitive function in CKD patients.

The urinary toxin aluminum can also pass through the blood-brain barrier and act on brain tissue. Aluminum is involved in metabolic processes and redox reactions in the central nervous system, and the level of aluminum in serum is a risk factor for AD ([@B1]). The accumulation of aluminum after renal dysfunction can contribute to cognitive decline and AD in CKD patients.

Cognitive function abnormalities are characteristic of hemodialysis patients, and hemodialysis patients have more cerebral atrophy, partly caused by cerebral ischemia during dialysis ([@B48]; [@B66]). Patients with impaired renal function are more prone to cognitive impairment, which is mainly due to renal anemia ([@B38]) and ischemic hypoxia of cells in the brain involved in the process of cognitive impairment in CKD patients.

The risks of cognitive impairment in AD patients with CKD are significantly higher than those in patients without CKD ([@B32]), not only in older CKD patients but also in young CKD patients (20--59 years old) ([@B28]). These risks can be explained by two factors: vascular injury and the direct neurotoxicity of uremic toxins caused by CKD. Figure [2](#F2){ref-type="fig"} shows the proposed mechanism for cognitive decline in AD patients with CKD.

![The mechanism about the cognitive decline or AD in CKD patients. The cognitive decline or AD can leaded by the accumulation of uremic toxins in serum through vascular injury and direct neurotoxicity in brain after renal failure, sunh as PTH, phosphorus, ADMA, etc.](fncel-12-00384-g002){#F2}

Common Risk Factors
-------------------

There are many common characteristics between the pathogenesis of AD and that of CKD, including vascular dysfunction or degeneration ([@B41]; [@B71]), aging ([@B8]; [@B36]), hypertension ([@B25]), diabetes ([@B67]) and hyperlipidemia ([@B56]; [@B70]; [@B46]). In addition, the expression level of APP in patients with kidney disease is higher, and a key protein, SorLA (sorting protein-related receptor), that regulates APP processing is simultaneously expressed in both kidney cells and neurons, and the gene's polymorphism is related to late-onset AD ([@B72]).

The Risk Assessment of AD in CKD Patients
-----------------------------------------

At present, diagnosis of AD is mainly determined by physicians' subjective experience and neuropsychological tests ([@B58]). Unfortunately, patients are already in late stages of the disease once AD clinical diagnoses are made. However, the best time to stop the progression of AD is before the onset of clinical symptoms. It is encouraging that we now understand not only that AD is related to CKD but also that both share similar pathological processes. This relationship may provide new insight into the pathogenesis of the disease since there are a few potential markers for the diagnosis of CKD and AD. For instance, we could validate whether there are any links between the biomarkers of CKD and AD and whether the biomarkers for CKD can be used for the diagnosis of AD.

The Potential Markers Related to AD
===================================

Aβ Protein, Aβ40/ Aβ42
----------------------

The traditional pathological hallmarks in the AD brain are neuron/synapse loss and the presence of large numbers of senile plaques and neurofibrillary tangles in the cerebral cortex and hippocampus. Aβ protein is a major component of senile plaques and can be secreted directly into cerebrospinal fluid (CSF) by neurons ([@B9]).

Interestingly, it was also found that serum Aβ levels were significantly higher in CKD patients ([@B34]), possibly due to the decreased clearance of Aβ protein in the blood of CKD patients, suggesting that cognitive decline and AD related to CKD can be affected by Aβ protein in CKD patients. Many studies have reported that Aβ40/Aβ42 levels were significantly increased in the CSF of AD patients, and this parameter is very sensitive and specific ([@B29]; [@B10]).

Tau Protein
-----------

Neurofibrillary tangles are another characteristic pathological change in the AD brain, and abnormally phosphorylated tau proteins are the main constituent proteins of neurofibrillary tangles ([@B11]). An increase in tau protein/phosphorylated tau (p-tau) in the CSF is a sign of AD ([@B75]). Moreover, studies show that changes in the tau protein can be associated with the pathology of AD after the elevation of aluminum in renal dialysis patients (CKD~5~) ([@B31]).

Serum Homocysteine
------------------

Serum homocysteine (Hcy) is a sulfur-containing amino acid ([@B12]). As mentioned above, serum Hcy clearance is significantly decreased in patients with CKD and patients already prone to high Hcy in the blood ([@B35]; [@B65]). Interestingly, serum Hcy levels were found to be significantly higher in AD patients ([@B8]), and serum Hcy levels are a strong and independent risk factor of AD and dementia ([@B71]). Serum Hcy is involved in the pathogenesis of AD through endothelial cell dysfunction and small blood vessels by oxidative stress ([@B8]). Moreover, CKD is an independent risk factor for increased serum Hcy levels ([@B15]), and the elevation of Hcy caused by CKD was found to be associated with the reduction in Aβ42 in the CSF ([@B29]). Thus, serum Hcy levels may be a novel maker of AD in patients with CKD.

The Potential Biomarkers Related to CKD
=======================================

Proteinuria, Creatinine, eGFR
-----------------------------

Proteinuria and eGFR are common indicators for renal function ([@B33]; [@B18]). Proteinuria is often found in patients with CKD. Under pathological conditions, the amount of protein in the urine increases, mainly due to damaged glomerular filtration barriers (endothelial cells, podocytes, glomerular basement membrane) and their increased permeability.

Glomerular filtration function is expressed by the GFR, \[mL/(min 1.73 m^2^)\], and the GFR is the amount of fluid produced by the two kidneys per unit of time. The GFR is currently calculated by the endogenous marker creatinine in the clinic. Creatinine is excreted by renal tubules and is not metabolized by the kidneys. In patients with CKD, excretion of creatinine by renal tubules is lower, the GFR is lower, and the serum concentration of creatinine is higher.

Proteinuria and eGFR are closely related to cognitive decline ([@B38]; [@B22]; [@B32]). One study found that the increase in ptau in the CSF and Hcy in the serum was significantly associated with a decrease in GFR in AD patients ([@B34]), suggesting that there is a connection between CKD and the increase in ptau in the CSF. Additionally, the creatinine level was closely related to cognitive impairment ([@B47]).

Hemoglobin Concentration
------------------------

Erythropoietin (EPO) is mainly produced in the kidney ([@B7]); EPO promotes the formation of red blood cells and maintains normal hemoglobin concentrations. The concentrations of hemoglobin and EPO in the serum of CKD patients are significantly lower, and CKD patients are more prone to anemia and anemic hypoxia ([@B39]).

A large cohort study with 3591 subjects found that CKD patients were more likely to exhibit cognitive decline. However, after adjusting for hemoglobin concentration, this link became weak or disappeared ([@B38]), suggesting that this strong correlation was mainly caused by the change in hemoglobin concentration in CKD patients. The level of hemoglobin in the serum was significantly correlated with cognitive impairment. Additionally, studies have demonstrated that EPO can have neuroprotective effects ([@B23]), the production of EPO can be stimulated by anemic hypoxia in the brain, and anemia is an independent risk factor of cognitive decline ([@B64]).

Cystatin C
----------

The concentration of cystatin C is mainly determined by the GFR because the kidney is the only organ that cleanses cystatin C ([@B37]). Research confirms that the gene encoding cystatin C (CST3) is a susceptible gene of late-onset AD. In addition, it has been found that cystatin C and Aβ colocalize in the amyloid deposition of brain parenchyma and cerebral vessels of AD patients ([@B59]), and this study also found colocalization of cystatin C and APP in transfected cells and cell membranes through immunofluorescence analysis and a combination of cystatin C, full-length APP and secreted βAPP through western blots of immunoprecipitated cell lysates and culture proteins ([@B24]).

The levels of cystatin C in the plasma of AD patients were lower than those in the age-matched control group ([@B16]). It is unclear whether the deposition of cystatin C in the brain leads to a decrease in cystatin C in the peripheral plasma. Furthermore, if cystatin C concentrations increase in the plasma of CKD patients, it is unclear whether this would help promote binding and precipitation between cystatin C and APP in the brain. The level of cystatin C in the serum may be a potential new biomarker of AD and cognitive decline in CKD patients.

Urotoxin
--------

Uremic toxins have been among the most studied factors leading to uremia since 1840 when P.A. Piorry and D.I. Heritier proposed the concept of uremia ([@B57]). It has been found that there are more than 90 kinds of urinary toxins in uremic patients ([@B21]), but their impact on the body is not clear. In recent years, increasing attention has been focused on small molecule toxins and intermediate-sized molecule toxins, such as PTH ([@B49]; [@B51]), phosphorus, aluminum and ADMA. Some studies have found a significant increase in PTH in the blood of patients with CKD ([@B63]; [@B44]), and PTH is closely related to a decline in cognitive function ([@B45]). Additionally, phosphorus and ADMA have confirmed involvement in the progress of vascular injury ([@B68]; [@B60]). Some scholars have found that the level of aluminum is a risk factor for AD ([@B69]).

summary, numerous epidemiological studies demonstrate that there is a high incidence of cognitive impairment or AD-like dementia in CKD patients of all ages. This discovery highlights a new direction for the diagnosis and potential treatment of both CKD and AD. Vascular injury and the direct neurotoxicity of uremic toxins caused by renal dysfunction are the most reasonable mechanisms of the effects of CKD in AD patients. We might obtain unexpected results if we focus our attention on changes occurring in both the brain and the kidneys in further studies in the prevention and treatment of CKD and AD.
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